Pfizer Inc. Website Links For
Pfizer
 

Information About

Pfizer Inc.




  Company Logo
  Company Type Public ( NYSE : PFE )
  Company Slogan Working for a healthier world™
  Foundation Brooklyn , New York , USA (1849)
  Location New York City , New York , USA
  Key People Jeff Kindler , CEO<br/> David Shedlarz , VC<br /> Ian Read , Pres of Pharma<br/> John LaMattina , Pres of R&D<br/>
  Num Employees 106,000 (2005)
  Industry Health Care
  Products Accupril® <br /> Lipitor® <br /> Viagra® <br /> See Complete Products Listing
  Homepage wwwpfizercom
  Revenue $48371 billions USD (2% 2006)
  Net Income $19337 billions USD (139% 2006)


Pfizer Incorporated () is the world's largest research-based . It produces the number-one selling drug Lipitor ( Atorvastatin , used to lower blood cholesterol); the oral antifungal medication Diflucan ( Fluconazole ), the long-acting antibiotic Zithromax ( Azithromycin ), the well-known erectile dysfunction drug Viagra ( Sildenafil citrate), and the anti inflammatory Celebrex ( Celecoxib ) (also known as Celebra in some countries outside USA and Canada , mainly in South America).

Pfizer's Shares were made a component of the Dow Jones Industrial Average on April 8 , 2004 .

With 2005 actual spending of $7.4 billion in research & development (R&D), Pfizer boasts the industry's largest pharmaceutical R&D organization: Pfizer Global Research and Development.


HISTORY

Pfizer is named after in 1849. There, they produced an antiparasitic called Santonin . This was an immediate success, although it was the production of Citric Acid that really kick-started Pfizer's growth in the 1880s. Pfizer continued to buy property to expand its lab and factory on the block bounded by Bartlett Street; Harrison Avenue; Gerry Street; and Flushing Avenue. That facility is still utilized for Backshop purposes. Pfizer established its original administrative headquarters at 81 Maiden Lane in Manhattan.

By 1910, sales totaled nearly $3 million, and Pfizer became established as an expert in Fermentation technology. These skills were applied to the mass production of Penicillin during World War II , in response to an appeal from the US government. The antibiotic was urgently needed to treat injured Allied soldiers, and it soon became known as "the miracle drug". In fact, most of the penicillin that went ashore with the troops on D-Day was made by Pfizer.

By the 1950s, Pfizer was established in Iran, Belgium, Brazil, Canada, Cuba, Mexico, Panama, Puerto Rico and the United Kingdom.

During the 1980s and 1990s Pfizer underwent a period of growth sustained by the discovery and marketing of multiple successful drugs ( Zoloft , Lipitor , Norvasc , Zithromax , Aricept , Diflucan , Viagra ).


CORPORATE STRUCTURE

Current members of the , M. Anthony Burns , Robert Burt , Don Cornwell , William H. Gray , Constance Horner , William Howell , Stanley Ikenberry , Jeff Kindler (chairman), George Lorch , Dana Mead , Ruth J. Simmons , and William Steere .


Pfizer is organized into four divisions: Human Health ($44.28B in 2005 sales), Consumer Healthcare ($3.87B in 2005 sales), Animal Health ($2.2B in 2005 sales), and Corporate Groups (which includes legal, finance, and HR). On June 26, 2006, Pfizer announced that it would sell its Consumer Healthcare unit (famous for well-known brands like Listerine , Nicorette , Visine , Sudafed and Neosporin ) to Johnson & Johnson for $16.6B.1


MERGER AND ACQUISITION ACTIVITY


Pfizer was relatively conservative with regard to mega-mergers through stock-for-stock transactions through most of its history until 2000. In that year, William Steere retired from the company and was succeeded by Henry McKinnell . As can be noted with any stock analysis tool, Pfizer's per share price (adjusted for splits) went from about $50 to $30 from 1999 to 2006 during McKinnell's tenure. With roughly 7 billion shares outstanding, this reflects a loss in value of $140 billion under McKinnell's leadership pursuing a strategy of growth via stock for stock acquisition. Many industry analysts, however, criticize McKinnell for diluting shareholder value with these expensive stock-for-stock acquisitions that obviously paid a premium for the underlying value of the acquired company. Furthermore, internal contributions to the pipeline did not replace declining value nor did these M&A activities. McKinnell received record compensation which he staunchly defended against critics.


Warner-Lambert / Parke-Davis / Agouron

In 2000, Pfizer merged with Warner-Lambert and acquired full rights to Lipitor ( Atorvastatin ), the Blockbuster Statin previously jointly marketed by Warner-Lambert and Pfizer. Warner-Lambert was based in Morris Plains , New Jersey , where the company's former headquarters became a major base of operations for Pfizer. The facility, and Pfizer's consumer healthcare department, was sold to Johnson And Johnson in 2006 for $16.6 billion dollars.

Parke-Davis was acquired by Warner-Lambert in 1970, which in turn was bought by Pfizer in 2000. The headquarters of Parke-Davis was sold several years ago. The Parke-Davis research facilities in Ann Arbor, Michigan is planned to close in 2008.

Agouron Pharmaceuticals was acquired by Warner Lambert in 1999 and is now a subsidiary of Pfizer. Nelfinavir (Viracept®), an antiretroviral drug used in the treatment of the human immunodeficiency virus (HIV), was developed by Agouron Pharmaceuticals as part of a joint venture with Japan Tobacco Inc.


Pharmacia / Upjohn / Searle

Searle was founded in Omaha, Nebraska, in 1888. The founder was Gideon Daniel Searle. In 1908, the company was incorporated in Chicago. In 1941, the company established headquarters in Skokie, Illinois. It was acquired by the Monsanto company in 1985.

The Upjohn Company was a pharmaceutical manufacturing firm founded in 1886 in Kalamazoo , Michigan by Dr. William E. Upjohn , an 1875 graduate of the University Of Michigan medical school. The company was originally formed to make friable pills, which were specifically designed to be easily digested.

In 1995, Upjohn merged with Pharmacia AB , to form Pharmacia & Upjohn . Pharmacia was created in April 2000 through the merger of Pharmacia & Upjohn with the Monsanto Company and its G.D. Searle unit. The merged company was based in Peapack, New Jersey. The agricultural division was spun off from Pharmacia, as Monsanto, in preparation for the close of the acquisition by Pfizer.

In 2002, Pfizer bought Pharmacia, a competitor, to become the largest pharmaceutical company in the world. The merger was again driven in part by the desire to acquire full rights to a Blockbuster product, this time Celebrex ( Celecoxib ), the COX-2 Selective Inhibitor previously jointly marketed by Searle (acquired by Pharmacia) and Pfizer.


SUGEN

SUGEN, customarily written with capital letters, was founded in 1991 in ).


PRODUCTS

Pfizer manufactures pharmaceutical medications. Pfizer has an annual product marketing budget of $3 billion, which was the fourth-largest in the US as of 2003. Pfizer employs 38,000 sales representatives worldwide.2

In 2004 Pfizer’s Zoloft sales totaled $3.15 billion, contributing to 6.5% of Pfizer’s total revenue for 2004 and making it one of 19 drugs that generated more than $2 billion in revenues in the United States. Sciencemag.org In 2005, Zoloft sales totaled $3.5 billion, helping to make Pfizer one of the biggest drug makers in the world with approximately $51.3 billion in revenue for 2005.
In 2005 Pfizer Inc. spent $7.4 billion on research and development, making Pfizer Global Research and Development the largest pharmaceutical research and development organization. Pfizer homepage Guardian report


Development of Torcetrapib



Pharmaceuticals

The following is a list of key prescription pharmaceutical products. The names shown are all registered trademarks of Pfizer Inc.4



Animal health brands

The following is a partial list of Animal Health brands manufactured by Pfizer:



Over the Counter Product lines


The following is a partial list of Product lines previously manufactured by Pfizer but which were recently transferred to Johnson and Johnson in the sale of their Consumer Health division:



LEGISLATION AND LITIGATION

Pfizer is party to a number of suits stemming from companies it has acquired or merged with, including Asbestos litigation as well as litigation stemming from its Medicinal products.


Kelo case

Pfizer's interest in obtaining property in New London, Connecticut for expanded facilities led to the Kelo V. New London case before the U.S. Supreme Court .


Quigley Co.

Pfizer acquired Quigley in 1968, and the division sold Asbestos -containing insulation products until the early 1970s. Asbestos victims and Pfizer have been negotiating a settlement deal which calls for Pfizer to pay $430 million to 80 percent of existing plaintiffs. It will also place an additional $535 million into an asbestos settlement trust that will compensate future plaintiffs as well as the remaining 20 percent of current plaintiffs with claims against Pfizer and Quigley. The compensation deal is worth $965 million all up.

Of that $535 million, $405 million is in a 40-year note from Pfizer, while $100 million will come from insurance policies.


Bjork-Shiley heart valve

Pfizer purchased Shiley in 1979 at the onset of its Convexo-Concave valve ordeal, involving the Bjork-Shiley Heart Valve . Approximately 500 people died when defective valves failed and, in 1994, the United States ruled against Pfizer for ~$200 million.


Patients' rights legislation

Pfizer proposed a ban on all Lawsuit s against Manufacturers of Body Implant parts which was proposed in the United States Congress as part of Tort Reform legislation.


Off-label promotional practices

Access to pharmaceutical industry documents has revealed Marketing strategies used to promote Neurontin® for off-label use.6 In 1993, the US Food And Drug Administration (FDA) approved Gabapentin (Neurontin®, Pfizer) only for treatment of Seizures . Warner-Lambert , which merged with Pfizer in 2000, used activities not usually associated with sales promotion, including Continuing Medical Education and Research , sponsored articles about the drug for the medical literature, and alleged suppression of unfavorable study results, to promote gabapentin. Within 5 years the drug was being widely used for the Off-label treatment of pain and psychiatric conditions. In 2004, Warner-Lambert admitted to charges that it violated FDA regulations by promoting the drug for pain, psychiatric conditions, migraine, and other unapproved uses, and paid $430 million to resolve criminal and civil health care liability charges.7US Department of Justice Press Release: Warner-Lambert to pay $430 million to resolve criminal and civil health care liability charges Retrieved 14 August 2006


Philippines

In March 2006 Pfizer sued the Philippines government as well as two government health officials personally, to prevent Philippines drug regulators from allowing the importation of less expensive versions of a Pfizer heart disease drug.


Nigeria

In May 2006, '' The Washington Post '' published a Nigerian government report that had remained unreleased for five years. In this report, a panel of Nigerian medical experts found that Pfizer violated international law. This stems from the company's alleged testing of an unapproved drug, an oral form of Trovafloxacin , on children with Meningitis in Nigeria . Pfizer replied to the report saying they conducted the trial with full knowledge of the Nigerian government.8 These allegations Have Been the subject of litigation in both America and Nigeria. June 5, 2007 Nigerian federal government filed a civil lawsuit for $7 billion in damages against the drug maker, related to a study of an experimental Meningitis treatment given to children. Two hundred children received Trovan in Kano, Nigeria, in 1996, the company said. The Nigerian government and Kano state government allege Pfizer gave the antibiotic to children without proper parental consent and that it disabled or killed some children.[http://www.boston.com/business/healthcare/articles/2007/06/05/nigeria_suing_pfizer_over_study_of_drug/

In July 2007 the Nigerian government has filed criminal charges against Pfizer over the trials. {Link without Title}


RESEARCH AND DEVELOPMENT

Pfizer's human research and development organization is headquartered in New London, CT. The company has R&D labs in the following locations:
Groton , Connecticut ;
Sandwich , England ;
Nagoya, Japan ;
Amboise , France ;
La Jolla , California ;
Cambridge , Massachusetts ;
Kalamazoo , Michigan ;
St. Louis , Missouri .

In 2004, Pfizer invested $7.68 billion in research and development, the largest investment in R&D by private biomedical research organization.

In 2007, Pfizer announced plans to completely close the Ann Arbor, Nagoya and Amboise Research facilities by the end of 2008, eliminating 2,160 jobs and idling the $300-million dollar Michigan facility, which had seen millions of dollars of expansion in recent years. Pfizer's cuts blindside Ann Arbor workers , Kalamazoo Gazette, Sunday, January 23, 2007.

On June 18th, 2007 Pfizer announced it will move the Sandwich, England Animal Health Research (VMRD) division to Kalamazoo, Michigan . {Link without Title}


EMPLOYMENT & DIVERSITY

Pfizer received a 100% rating on the Corporate Equality Index released by the Human Rights Campaign starting in 2004, the third year of the report. In 2007, Pfizer's Canadian division was named one of Canada's Top 100 Employers , as published in Maclean's magazine, the only research-based pharmaceutical company to receive this honor.9


AIDS INVOLVEMENT

Pfizer has been involved in controversies over the medicine Diflucan (generic name fluconazole). In 1998, a campaign by Thai public health groups led to the elimination of the Pfizer monopoly on selling fluconazole in Thailand, and the price of the antifungal drug decreased from 200 baht to 6.5 baht in nine months, vastly expanding access to the medicine for AIDS patients. Faced with pressure for compulsory licenses to the Pfizer patent on this drug, Pfizer later established a program for limited access to the medicine in Africa.10

"In the United States, 46 percent of all new HIV/AIDS cases occur in the South. From 2003 -2006 the Pfizer Foundation has funded 23 innovative HIV/AIDS prevention programs and strengthened the capacity of community-based organizations to reach and serve their communities."11 Since 2003, Pfizer has committed a $3 Million grant toward supporting the Southern HIV/AIDS Prevention Initiative.

However, there are criticisms of the way Pfizer is testing its AIDS drug. "The European AIDS Treatment Group (EATG), collection of activists from 31 European Countries,12 said the design of the trial for Pfizer's CCR5 inhibitor maraviroc, previously known as UK-427,857, is putting people with HIV infection at unnecessary risk of developing AIDS."13

June 20, 2007 Maraviroc receives an approvable letter from the FDA advisory board. The letter was a product of expeditied review of the novel HIV compound.

In 2001, Pfizer asked the U.S. government to pressure the Brazilian government against issuing compulsory licenses for the patents on the AIDS drug nelfinavir.


AIDS Drugs Manufactured by Pfizer



SEE ALSO



NOTES



EXTERNAL LINKS